These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15176422)

  • 1. Genetic basis of drug-induced arrhythmias.
    Vos MA; Paulussen AD
    Ann Med; 2004; 36 Suppl 1():35-40. PubMed ID: 15176422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding drug-induced torsades de pointes: a genetic stance.
    Kannankeril PJ
    Expert Opin Drug Saf; 2008 May; 7(3):231-9. PubMed ID: 18462182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.
    van der Linde HJ; Van Deuren B; Somers Y; Loenders B; Towart R; Gallacher DJ
    Br J Pharmacol; 2010 Dec; 161(7):1444-54. PubMed ID: 21054337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsades de pointes and proarrhythmia.
    Ben-David J; Zipes DP
    Lancet; 1993 Jun; 341(8860):1578-82. PubMed ID: 8099651
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.
    Vargas HM
    Br J Pharmacol; 2010 Dec; 161(7):1441-3. PubMed ID: 20698854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetics of pro-arrhythmic adverse drug reactions.
    Petropoulou E; Jamshidi Y; Behr ER
    Br J Clin Pharmacol; 2014 Apr; 77(4):618-25. PubMed ID: 23834499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
    Thomsen MB; Beekman JD; Attevelt NJ; Takahara A; Sugiyama A; Chiba K; Vos MA
    Br J Pharmacol; 2006 Dec; 149(8):1039-48. PubMed ID: 17088870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic issues in thorough QT trials.
    Judson RS; Salisbury BA; Reed CR; Ackerman MJ
    Mol Diagn Ther; 2006; 10(3):153-62. PubMed ID: 16771601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM
    Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
    Lehtonen A; Fodstad H; Laitinen-Forsblom P; Toivonen L; Kontula K; Swan H
    Heart Rhythm; 2007 May; 4(5):603-7. PubMed ID: 17467628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
    Ritter JM
    Br J Clin Pharmacol; 2012 Mar; 73(3):331-4. PubMed ID: 22329611
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.